|Good article about Arecor - "experiencing significant growth":
"Dr Sarah Howell, CEO, Arecor commented on the move: "We're experiencing significant growth and we required enhanced facilities that could meet our expansion needs, both today and well into the future."
As Arecor's diabetes product moves into clinical trials and the organisation's partnerships with major pharma and biotech companies continue to expand, it expects to experience significant growth."|
|Interims out - NAV down to 69.1p due to the decline in SCLP's share price. SCLP is up some 10% since 30/6, so I would expect NAV to be up nearer say 71p now:
Hallmarq is still progressing very well. It's surely just a matter of time before it IPO's on AIM, at which point I'd expect NAV serious upside.
I'm also hopeful for the £450k carrying value in AIM-quoted ODX - this could be worth a lot more in a few months' time with decent news flow.|
|More good news from Arecor:-
|This looks like huge news for Hallmarq (only posted recently on their web site):
"Hallmarq signs agreement with VCA, North America’s biggest veterinary hospital network
Mon, Mar 21, 2016 15:33 CET
"VCA animal hospitals (VCA), North America’s largest network of over 600 small animal veterinary hospitals, has signed an agreement with Hallmarq Veterinary Imaging for the supply of their high field PetVet 1.5 T Companion Animal MRI. The agreement follows a comprehensive review of the technical capabilities of PetVet and the support provided by Hallmarq. VCA has 83 specialist clinics and over 400 board certified specialists that are likely to require in-house MRI.
Jos Belgrave, CEO of Hallmarq Veterinary Imaging said that this was an agreement that both parties have been working towards for some time, “Like Hallmarq, VCA prefers to partner with key suppliers over a longer period of time, rather than to simply process one-off transactions. It was therefore very important that the management team and specialists were sure that Hallmarq could deliver across critical areas.”
An important consideration for VCA was the high quality images generated by PetVet, which are a result of the veterinary specific coil design and custom sequences. The experts at VCA appreciated the ease of use that allows veterinary nurses or technicians to be trained to operate the system and the experienced Hallmarq support team and training that comes as part of the PetVet package. Once the company was satisfied with the technical aspects of the MRI, other factors such as the installation and running costs were also factored in.
Dr. Steve Fisher, Vice President of Strategic Partnerships for VCA says access to advanced diagnostics is essential for its network of specialists, “Pet health is our priority and excellent service is our goal.”
Hallmarq is a rapidly growing company with offices in the UK, North America and Australia and has recently received major awards in innovation and international trade. Jos Belgrave says Hallmarq is delighted to be working with VCA, “It’s an accolade to our core team that an organisation the size of VCA that focuses so firmly on excellence, has decided to look to Hallmarq when considering sourcing best-in-class diagnostic imaging. Our equine MRI broke new boundaries when it launched and we are building a strong reputation in companion animal as our advanced technology becomes more widely known. The new PetVet MRI is based on a magnet which is currently used in over 200 human hospitals around the world, while the Hallmarq software has been driving its Equine MRI for over 10 years. "|
|Excellent news from ImmBio....
"Vaccine against pneumonia passes first trial
By CambridgeNews | Posted: June 30, 2016
A new vaccine against a major cause of pneumonia has passed the first big test.
ImmBio, based at Babraham, reports positive results from the First-in-Human study of PnuBioVax which acts against the bacterial pathogen Streptococcus pneumoniae.
The new vaccine proved safe and well tolerated by a group of healthy adults who took part in the first clinical trial and triggered antibody responses.
The data is presented today at the International Symposium on Pneumococci and Pneumococcal Diseases in Glasgow.
"The results of this study have demonstrated the safety of PnuBioVax in adults, and we are now looking at developing the vaccine further, focusing on the at-risk populations for pneumococcal disease of the young and the elderly," said Dr Chris Bailey, Development Director at ImmBio.
Graham Clarke, CEO, added: "Demonstrating that PnuBioVax is safe and immunogenic through this phase I clinical study is a fundamental step in our mission to create a universal vaccine against pneumococcal disease.
"This provides the real prospect of a strain-independent pneumococcal disease prophylactic vaccine. We are now looking for partners to progress PnuBioVax through late stage clinical development, manufacturing and marketing."|
Here's a good report from this year's AGM:
SCLP is now above 20p, so HYG's NAV may well be around 74p or so.
Hallmarq sounds extremely promising - another 40p+ of NAV uplift is apparently possible. Timing will depend on when Hallmarq believe they can IPO.|
|More good news from an investee company:-
|I see that HYG have another new major shareholder - David Blundell now has 3.2% with 261,000 shares:
Is this the same Blundell who co-founded Sharesoc I wonder?
|RNS out - looks like James Leek bought those shares above as he's increased by 165,000 to 465,500 shares, or 5.6%:
Timmbo, any ideas on James Leek and his intentions/thoughts?|
|Looks like someone bought 160,000 shares at 66p this morning. That's almost 2% of the company.|
|Worth noting that ODX and EKF are also rising nicely as well as SCLP, especially ODX after today's news.
Today could be a turning point for HYG in terms of NAV. I'll try and update the thread header when I get a chance for the latest shareholdings in SCLP etc.|
|SCLP rocketing on the immunotherapy drug news all over the media this morning....
Many thanks for the AGM report timbo. Interesting times!|
|I have written up a few notes on the AGM on The Motley Fool
That's the most exciting one I've been to so far!|
|AS you can probably gather from the RNS yesterday, the AGM on Thursday was an exciting affair:
|NAV now almost 89p with SCLP, EKF and ODX all rising.
With a large sum invested in OR Productivity it's great to see them starting to break even.
And Hallmarq continues to make very good progress, with lots of good news on its web site:
|There was an interesting (but ambiguous) announcement from one of the AIM quoted investee companies this morning (EKF) which may be a prelude to a liquidity event:
This follows shortly after an industry veteran declaring a strategic stake:
|The 2014 results are just out - NAV of 90.4p per share:
Mixed bag really. SCLP and ODX's valuations will have slipped since, but I'm sure Hallmarq must be worth a lot more than the current HYG valuation, which would be crystallised on their IPO.
The Report states "As mentioned later in this statement, several portfolio companies are planning to list on AIM in 2015 and 2016". I can only see reference to Hallmarq in this regard.
Interesting stuff re the broker collaboration for shareholder investment into the portfolio. This is a great idea.|
|rivaldo. I know, I really didn't want to sell but I thought the possibility of HYG going with the trend and falling off a cliff was too strong. Actually it looks now like that might not happen. I may well buy back before too long, although it seems a bit odd buying second hand VCTs without the upfront tax advantage. I have used some of the proceeds to buy some EKF which I also think has a very good long term outlook. Best regards SBP|
|Good luck sbp. I really believe you should keep a sharp eye on HYG - Hallmarq is going from strength to strength and should repay an investment here in time imho. And SCLP may today have reversed its trend!|
|Having held these since launch I have just (rather sadly) sold them. Scancell has dropped off a cliff and Oxford VCT has followed, made me too nervous. Shame, I really like the portfolio here. Might even buy back once Scancell becomes clear. GLA
Best regards SBP|
|Bit of buying today - and it sounds like Glide Pharma are progressing nicely following successful pre-clinical results:
"Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product
26 Jan 2015
OXFORD, UK – 26 January 2015 - Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that it has appointed Albany Molecular Research (Glasgow) Limited (AMRI) to manufacture the company’s novel solid dose injection (SDI) formulation of octreotide, for use in a human bioequivalence study to be conducted in Q4 2015. The appointment follows successful pre-clinical proof-of-concept results, which compared the solid formulation with the currently marketed liquid product (Sandostatin®).
|Encouraging to see SCLP up to 38.75p. My rough calculation (without a calculator!) has HYG's NAV at around 102p at that level.|
|Cooment on Glide from today's Oxford Tech VCT results:
"Glide remains on track for a proof of concept clinical trial in 2015"
And on Scancell:
"Scancell has a vaccine for skin cancer in clinical trials. Early indications on animals are that when Scancell's vaccine is used in combination with checkpoint inhibitors, the success rate for the treatment rises from around 50% to around 85%. If this is borne out by future trials, then Scancell's value may increase significantly. "|
|Continuing to move up slowly.
Timbo and myself were at the AGM of Surface Transforms (SCE) recently - their non-exec is Kevin D'Silva, who is also Chairman of Hallmarq. Apart from being extremely pleasant, he confirmed that things at Hallmarq were going very well, confirming my confidence that this could be an extremely good investment for HYG.
OT : SCE are also well worth a look imho. At a mere £7m m/cap the upside after last week's "game-changer" RNS may be huge.|